Brokerages predict that Genocea Biosciences Inc (NASDAQ:GNCA) will announce earnings of ($0.14) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Genocea Biosciences’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.15). Genocea Biosciences posted earnings per share of ($0.54) in the same quarter last year, which suggests a positive year over year growth rate of 74.1%. The business is expected to announce its next quarterly earnings results on Wednesday, August 8th.
On average, analysts expect that Genocea Biosciences will report full-year earnings of ($0.68) per share for the current financial year, with EPS estimates ranging from ($0.74) to ($0.62). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.86) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14).
A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System increased its stake in Genocea Biosciences by 166.6% in the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 78,469 shares during the last quarter. GSA Capital Partners LLP increased its stake in Genocea Biosciences by 266.9% in the 1st quarter. GSA Capital Partners LLP now owns 234,065 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 170,265 shares during the last quarter. NEA Management Company LLC acquired a new stake in Genocea Biosciences in the 1st quarter valued at $26,250,000. BlackRock Inc. increased its stake in Genocea Biosciences by 169.1% in the 1st quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock valued at $4,159,000 after buying an additional 2,488,540 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Genocea Biosciences by 164.5% in the 1st quarter. Northern Trust Corp now owns 792,677 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 492,961 shares during the last quarter. Hedge funds and other institutional investors own 61.94% of the company’s stock.
GNCA traded down $0.02 during trading on Friday, hitting $0.91. The company had a trading volume of 384,538 shares, compared to its average volume of 467,098. The stock has a market capitalization of $80.76 million, a P/E ratio of -0.46 and a beta of 1.20. Genocea Biosciences has a one year low of $0.79 and a one year high of $6.78. The company has a current ratio of 8.06, a quick ratio of 8.06 and a debt-to-equity ratio of 1.00.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.